Navigation Links
Kensey Nash Announces Director Resignation
Date:2/4/2009

EXTON, Pa., Feb. 4 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today announced the resignation of Mr. Jeffrey C. Smith, Partner and Portfolio Manager of Ramius LLC, from its Board of Directors.

Mr. Smith became a director of Kensey Nash in December 2007 and was a member of the Corporate Governance and Nominating Committee as well as a member of the Strategic Planning Committee. Mr. Smith advised the Company that he has resigned from the Board and Board committees given time constraints and other responsibilities that demand his attention.

"On behalf of the Board, I would like to thank Jeff for his service and contributions to Kensey Nash and wish him well with his future endeavors," stated Joe Kaufmann, President and CEO.

"Over the past 14 months, the Company has accomplished a great deal in a relatively short period of time including successfully executing on the sale of the Endovascular products segment and materially increasing cash flow and earnings," commented Jeff Smith. "At this time, I must shift my focus to other opportunities which demand my attention. I enjoyed serving on the Board of Directors and look forward to monitoring the Company's continued success."

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
2. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
3. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
4. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
5. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
6. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
7. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
8. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
9. Kensey Nash Reports Third Quarter Record Revenue and Sales
10. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
11. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s ... the tips of your toes. Foot massage, whether administered by a professional masseuse or ... relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has taken ...
(Date:2/5/2016)... Rafael, CA (PRWEB) , ... February 05, 2016 , ... ... with ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ChildLight ... New Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder Lisa ...
(Date:2/5/2016)... ... 05, 2016 , ... Give To Cure today announced that it ... to Give To Cure’s campaign that is crowdfunding clinical trials to help find cures ... payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... In sleep, ... form as a dream. A hallmark feature of patients with eating disorders is significant ... The eating disorder behaviors and obsessions are regarded as maladaptive means for coping with ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Frontier Pharma: ... Commercializing First-in-Class Innovation Chronic Obstructive ... with chronic inflammation of the airways and lungs. ... symptoms make the disease one of the leading ... death in the world. COPD is linked to ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
(Date:2/4/2016)... , Feb. 4, 2016  Blueprint Medicines ... discovering and developing highly selective investigational kinase medicines ... the appointment to its board of directors of ... with nearly 30 years of industry-related experience. ... of Blueprint Medicines. "Lonnel,s strong strategic experience developing ...
Breaking Medicine Technology: